Psoriasis Drug Market Share, Size, Trends, Industry Analysis Report, By Therapeutic Class; By Type (Psoriatic Arthritis, Plaque Psoriasis, Other); By Treatment Type (Topical, Systematic, Biologics); By Region; Segment Forecast, 2024 - 2032

The psoriasis drug market size is expected to reach USD 56.96 billion by 2034, according to a new study by Polaris Market Research. The report “Psoriasis Drug Market Size, Share, Trends, Industry Analysis Report: By Class (Tumor Necrosis Factor Inhibitors, Interleukin Inhibitors, Vitamin D Analogues, Corticosteriods, and Others), Type, Treatment, Route of Administration, Distribution Channel, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The psoriasis drug market demand is driven by the rising prevalence of psoriasis, growing awareness of advanced treatment options, and increasing adoption of biologics and targeted therapies. Key opportunities lie in the development of biosimilars and innovative drug delivery systems, addressing the unmet needs of underserved patient populations, particularly in emerging markets.

Psoriasis drug market trends such as the shift toward personalized medicine, advancements in digital health integration, and combination therapies are shaping the market landscape. Continuous research and regulatory approvals for novel therapies are propelling innovation and expanding treatment options, contributing to the market growth and evolution.

Psoriasis Drug Market Report Highlights

Based on class, the interleukin inhibitors segment dominates the psoriasis drug market share due to their high efficacy and safety in managing moderate-to-severe psoriasis, while ongoing innovations drive their rapid growth.

The biologics segment, by treatment, holds the largest share and is the fastest-growing segment, driven by their targeted approach and widespread adoption for severe psoriasis cases.

By route of administration, the parenteral segment leads the psoriasis drug market revenue share, supported by the growing use of injectable biologics, which also exhibit the highest growth due to improved delivery technologies.

The hospital pharmacies segment, by distribution channel, dominates the market, benefiting from their role in dispensing biologics, while their growth is driven by the increasing prevalence of severe cases requiring specialized care.

North America dominates the psoriasis drug market share due to advanced healthcare infrastructure and high adoption of biologics. However, Asia Pacific is the fastest-growing region, driven by increasing healthcare investments and expanding access to advanced therapies.

Polaris Market Research has segmented the psoriasis drug market report on the basis of class, type, treatment, route of administration, distribution channel, and region:

By Class Outlook (Revenue – USD Billion, 2020–2034)

Tumor Necrosis Factor Inhibitors

Interleukin Inhibitors

Vitamin D Analogues

Corticosteriods

Others

By Type (Revenue – USD Billion, 2020–2034)

Psoriatic Arthritis

Plaque Psoriasis

Others

By Treatment Outlook (Revenue – USD Billion, 2020–2034)

Topicals

Systemic

Biologics

By Route of Administration Outlook (Revenue – USD Billion, 2020–2034)

Oral

Parenteral

Topical

By Distribution Channel Outlook (Revenue – USD Billion, 2020–2034)

Hospital Pharmacies

Retail Pharmacies

Others

By Regional Outlook (Revenue – USD Billion, 2020–2034)

North America

• US
• Canada

• Germany
• France
• UK
• Italy
• Spain
• Netherlands
• Russia
• Rest of Europe

• China
• Japan
• India
• Malaysia
• South Korea
• Indonesia
• Australia
• Vietnam
• Rest of Asia Pacific

• Saudi Arabia
• UAE
• Israel
• South Africa
• Rest of Middle East & Africa

• Mexico
• Brazil
• Argentina
• Rest of Latin America